Literature DB >> 18276200

The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre.

Megan W France1, Mary E Dodd, John R Govan, Catherine J Doherty, A K Webb, Andrew M Jones.   

Abstract

BACKGROUND: This study reviews the impact of changing infection control practices at the Manchester Adult Cystic Fibrosis Centre (MACFC) upon the epidemiology of Burkholderia species infections.
METHODS: We reviewed strain and genomovar typing of all available Burkholderia isolates at our centre between 1983-2006.
RESULTS: The incidence/prevalence of infection with Burkholderia species between 1983-1990 was below 5%/9% each year. There was a rise in incidence/prevalence of Burkholderia species between 1991 and 1994 with a peak of 16.3%/31.2% in 1992. Following complete cohort segregation, the incidence has fallen to below 3% for all but one year and the prevalence has gradually reduced to 9.3% in 2005. Currently, there is an increase in the prevalence to 10.6% for the first time since 1994, predominantly due to patients with unique infections transferring into the unit from referring centres. The presence of unique strains now exceeds transmissible strains for the first time since 1991.
CONCLUSIONS: Infection control measures including patient segregation have controlled spread of transmissible B. cenocepacia strains, but not the acquisition of unique strains. Unique strains of Burkholderia species now account for the majority of new infections at the Manchester Adult Cystic Fibrosis Centre.

Entities:  

Mesh:

Year:  2008        PMID: 18276200     DOI: 10.1016/j.jcf.2008.01.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  9 in total

1.  Unusual distribution of Burkholderia cepacia complex species in Danish cystic fibrosis clinics may stem from restricted transmission between patients.

Authors:  Niels Nørskov-Lauritsen; Helle Krogh Johansen; Mette G Fenger; Xiaohui C Nielsen; Tacjana Pressler; Hanne V Olesen; Niels Høiby
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

2.  Microbial Community Distribution and Core Microbiome in Successive Wound Grades of Individuals with Diabetic Foot Ulcers.

Authors:  Apoorva Jnana; Vigneshwaran Muthuraman; Vinay Koshy Varghese; Sanjiban Chakrabarty; Thokur Sreepathy Murali; Lingadakai Ramachandra; Kallya Rajgopal Shenoy; Gabriel Sunil Rodrigues; Seetharam Shiva Prasad; Dhananjaya Dendukuri; Andreas Morschhauser; Joerg Nestler; Harald Peter; Frank F Bier; Kapaettu Satyamoorthy
Journal:  Appl Environ Microbiol       Date:  2020-03-02       Impact factor: 4.792

Review 3.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

4.  Relationship between Physical Activity and Fatigue in Adults with Cystic Fibrosis.

Authors:  Carly Orava; Jennifer Fitzgerald; Stephen Figliomeni; Danette Lam; Anthony Naccarato; Erika Szego; Karen Yoshida; Pat Fox; Jenna Sykes; Kenneth Wu
Journal:  Physiother Can       Date:  2018       Impact factor: 1.037

5.  Burkholderia cepacia complex in Serbian patients with cystic fibrosis: prevalence and molecular epidemiology.

Authors:  Z V Vasiljevic; K Novovic; M Kojic; P Minic; A Sovtic; S Djukic; B Jovcic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-13       Impact factor: 3.267

6.  Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis.

Authors:  Kay A Ramsay; Claire A Butler; Stuart Paynter; Robert S Ware; Timothy J Kidd; Claire E Wainwright; Scott C Bell
Journal:  J Clin Microbiol       Date:  2013-09-18       Impact factor: 5.948

7.  Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Authors:  Josephine M Bryant; Dorothy M Grogono; Daniela Rodriguez-Rincon; Isobel Everall; Karen P Brown; Pablo Moreno; Deepshikha Verma; Emily Hill; Judith Drijkoningen; Peter Gilligan; Charles R Esther; Peadar G Noone; Olivia Giddings; Scott C Bell; Rachel Thomson; Claire E Wainwright; Chris Coulter; Sushil Pandey; Michelle E Wood; Rebecca E Stockwell; Kay A Ramsay; Laura J Sherrard; Timothy J Kidd; Nassib Jabbour; Graham R Johnson; Luke D Knibbs; Lidia Morawska; Peter D Sly; Andrew Jones; Diana Bilton; Ian Laurenson; Michael Ruddy; Stephen Bourke; Ian Cjw Bowler; Stephen J Chapman; Andrew Clayton; Mairi Cullen; Thomas Daniels; Owen Dempsey; Miles Denton; Maya Desai; Richard J Drew; Frank Edenborough; Jason Evans; Jonathan Folb; Helen Humphrey; Barbara Isalska; Søren Jensen-Fangel; Bodil Jönsson; Andrew M Jones; Terese L Katzenstein; Troels Lillebaek; Gordon MacGregor; Sarah Mayell; Michael Millar; Deborah Modha; Edward F Nash; Christopher O'Brien; Deirdre O'Brien; Chandra Ohri; Caroline S Pao; Daniel Peckham; Felicity Perrin; Audrey Perry; Tania Pressler; Laura Prtak; Tavs Qvist; Ali Robb; Helen Rodgers; Kirsten Schaffer; Nadia Shafi; Jakko van Ingen; Martin Walshaw; Danie Watson; Noreen West; Joanna Whitehouse; Charles S Haworth; Simon R Harris; Diane Ordway; Julian Parkhill; R Andres Floto
Journal:  Science       Date:  2016-11-11       Impact factor: 47.728

8.  Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity.

Authors:  Cédric Lood; Charlotte Peeters; Quentin Lamy-Besnier; Jeroen Wagemans; Daniel De Vos; Marijke Proesmans; Jean-Paul Pirnay; Fedoua Echahidi; Denis Piérard; Matthieu Thimmesch; Anca Boeras; Katrien Lagrou; Evelien De Canck; Elke De Wachter; Vera van Noort; Rob Lavigne; Peter Vandamme
Journal:  PLoS Pathog       Date:  2021-03-15       Impact factor: 6.823

9.  Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?

Authors:  Alex Horsley; Kevin Webb; Rowland Bright-Thomas; John Govan; Andrew Jones
Journal:  Front Cell Infect Microbiol       Date:  2011-12-21       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.